Clinical Trial Update: A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports that SHR-1826 is being studied in combination with other antitumor therapies for non-small cell lung cancer in Phase 1/Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SHR-1826

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: RECRUITING